Search for a trial

A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

The purpose of this study is to find out if patients with locally advanced/metastatic Radioactive Iodine-refractory (RAI) thyroid cancer (papillary, follicular or Hurthle cell carcinoma), will benefit from sorafenib treatment compared to patients…

A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)

The primary objective is to investigate the efficacy, safety and tolerability of RV 001 (a fully human anti-IGF-1R antibody) administered q3W for 6 months, in comparison to placebo, in the treatment of patients suffering from active TED.Secondary…

The effect of a self controlled dose of Levothyroxine on the quality of life and thyroid stimulating hormone in patients treated for hypothyroidism: a randomized, double blind, consecutive study.

The goal of this study is to positively influence quality of life in patients with hypothyroidism by giving them back control in their treatment. We also want to see what the placebo effect will be. And at last we want to check if patients have the…

Evening versus Morning Administration of Levothyroxine: a randomised controlled double-blind trial

To study in a large randomised double-blind trial, if the administration of levothyroxine at bedtime significantly changes TSH and thyroid hormone levels compared to morning administration. Furthermore we want to evaluate the change of quality of…

EFFECTS OF RANDOMIZED, DOUBLE-BLIND, MULTIPLE DOSE ADMINISTRATION OF OLANZAPINE OR TOPIRAMATE PLUS OLANZAPINE ON THYROID FUNCTION, GLUCOSE AND LIPID METABOLISM IN HEALTHY MALES

The objective of the study is to observe the effect of olanzapineat a dose of 10 mg daily for 14 days when given with/without topiramaat at a dose of 25 and 50 mg twice daily on bodyweight in healthy male subjects. In addition the effect of…

A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with eitherc differentiated and medullary thyroid carcinoma progressing after first line therapy.

The primary objective is to explore the efficacy of nintedanib (as measured by progression free survival) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.

Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Placebo-controlled Study

This study has been transitioned to CTIS with ID 2024-516124-34-00 check the CTIS register for the current data. Primary Objective:• To evaluate the effects of withdrawal of tiratricol treatment (placebo group) on serum total triiodothyronine (T3)…